Drug Drug Interaction of BI 201335 and Tenofovir

Inclusion criteria

• Healthy males and female subjects and according to medical history, including the physical examination, vital signs (blood pressure, pulse rate), 12-lead electrocardiogram and clinical laboratory tests; all with acceptable findings.
• Age =18 to =55 years
• Weighing at least 50 kg, and body mass index >=18.5 and BMI 24:00 hours within at least one month or less than ten half lives of the respective drug before enrollment in the study (with the exception of hormonal contraceptives).
• Use of any drugs which might influence the results of the trial up to 7 days prior to enrolment as nutraceuticals and herbal remedies that would interfere with either the absorption, distribution or metabolism of BI 201335 NA, or that prolong the QT/QTc interval.
• Use of any investigational drug within 30 days prior to enrollment; or the planned use of any investigational drug during the course of the current study.
• Smoking (>10 cigarettes or >3 cigars or >3 pipes/day)
• Inability to abstain from smoking more than 3 cigarettes/day during the period of dosing with study medication.
• Drug and alcohol abuse (>60g/day).
• Blood donation (more than 100 mL within four weeks prior to administration or during the trial).
• Excessive physical activities within one week prior to administration or during the trial.
• Any laboratory value outside the reference range that is of clinical relevance at screening, according to the judgment of the investigator, and in consultation with the clinical monitor.
• Known elevated liver enzymes in past with any compound (experimental or marketed).
• Concomitant administration of any food product known to alter P450 enzyme activity such as grapefruit juice, Seville oranges, St. John's Wort.
• Concomitant administration of oral contraceptives (subjects who stopped oral contraceptives at least 7 days prior to Day 1 may be included.
• Inadequate venous access.
• A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTcF, or QTcB interval >450 ms).
• Infection with hepatitis B (HBV), or hepatitis C virus (HCV),
• Positive test for HIV-1 or HIV-2. For women of child bearing potential (WOCBP)
• Pregnancy or planning to become pregnant within 2 months of study completion
• Positive pregnancy test at screening visit
• No proof of sterilization, or not willing or unable to consistently use an acceptable method of double barrier contraception including IUD, or diaphragm with spermicidal cream/jelly and condoms for male partner, during and up to 3 months after completion/termination of the trial.
• Lactation period with active breastfeeding from time of screening to 30 days after end of trial visit.

For male subjects

• No proof of sterilization, or not willing or unable to consistently use an acceptable method of double barrier contraception including a condom each time and female partner of child bearing potential consistently uses oral birth control pills, or an IUD, or a diaphragm with spermicidal cream/jelly). Male subjects must not father a child from administration of the first dose and up to 3 months after the last dose of study medication.